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Summary In order to understand in more detail the mechanism underlying the preferential hypoxic cytotoxi-
city of the benzotriazine N-oxide SR 4233, we have compared the hypoxic cytotoxicity of this drug to the rates
of hypoxic metabolism in both DNA double strand break repair-competent and repair-deficient cell cultures.
Rodent SCCVII cells and repair deficient, radiation sensitive cells (rodent XR-1, V-3, and human AT5BI) were
most sensitive to SR 4233 under hypoxia with a lethal dose needed to kill 50% of cells (LDm0) of <5 ZM.
SR 4233 was less cytotoxic to human AG 1522 (LD50 = 18 pM), CHO4364 (LD50=25 gM) and human
HT 1080 cells (LD50 = 33 giM). The sensitivities to SR 4233 were found to be inversely proportional to the rates
of SR 4233 metabolism in repair-competent cells (R2 = 0.9). However, XR-1 and V-3 cells were more sensitive
to SR 4233 than predicted by the metabolism rate. Thus, the toxicity by SR4233 towards hypoxic cells
appears to result from two mechanisms; the rate of drug metabolism and the ability to repair DNA double
strand breaks.
Solid tumours contain viable hypoxic cells which are resistant
to killing by both radiation and chemotherapeutic drugs
(Tannock & Guttman, 1981; Thomlinson & Gray, 1955). One
strategy to overcome this problem of hypoxic cells in solid
tumours would be to combine traditional cancer therapy
regimens with the use of agents that are preferentially toxic
to hypoxic cells. SR 4233, a benzotriazine di-N-oxide, is cur-
rently being evaluated as a bioreductive cytotoxin to
specifically kill hypoxic cells (Figure 1). The drug has a high
selective toxicity for hypoxic cells in vitro (Zeman et al.,
1986) and is effective as an antitumour agent in vivo when
combined either with radiation (Zeman et al., 1988; Brown &
Lemmon, 1990) or with an agent which specifically induces
tumour hypoxia (Brown 1987; Sun & Brown, 1989). SR 4233
is reduced in hypoxic cells to form the two- and four-electron
reduction products, SR 4317 and SR 4330, as measured by
HPLC (Baker et al., 1988; Laderoute & Rauth, 1986; Walton
et al., 1989). Both of these products are nontoxic to cells
under hypoxic or aerobic conditions (Baker et al., 1988;
Zeman et al., 1986). We have proposed that SR 4233 is
reduced via a single- electron reduction pathway to form a
free radical intermediate, the structure of which has been
recently confirmed by ESR (Lloyd & Mason, personal com-
munication). Under aerobic conditions, the radical reacts
with oxygen in a futile one-electron reduction cycle,
generating superoxide in the process (Laderoute et al., 1988).
In the absence of oxygen, the SR 4233 radical may abstract
hydrogen from DNA and other macromolecules, forming
strand breaks which ultimately result in cell death. The
major enzyme responsible for the bioreduction of SR 4233
appears to be P-450, both in liver microsomes (Walton et al.,
1989), and in human tumour cells (Wang et al., in prepara-
tion).
Recent studies indicate that mammalian cell lines display
marked variations in the hypoxic cytotoxicities to SR 4233
(Brown & Kuruppu, unpublished). In order to understand
these variations, we have measured the hypoxic cytotoxicity
of SR 4233 in cells displaying different radiation sensitivities
with known defects in DNA repair and have simultaneously
determined the reductive metabolism of the drug by measur-
ing the rate of formation of the fluorescent, 1-oxide reduction
product, SR 4317. The sensitivities to SR 4233 in repair-
proficient cells was found to correlate well with the rates of
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Figure 1 Chemical structure of SR 4233 and its 1- and 2-oxide
reduction products.
drug metabolism in these cells. In addition, we found that
cells deficient in DNA strand break rejoining were more
sensitive to SR 4233 killing under hypoxia than expected
from their rates of metabolism.
Materials and methods
Cells and cell cultures
Human AG 1522 and HT 1080 cells were originally obtained
from the American Culture Collection. AT5BI fibroblasts
were obtained from the NIGS Human Genetic Mutant Cell
Repository, Institute For Medical Research. SCCVII cells are
a tissue culture adapted cell line of a squamous cell car-
cinoma which arose spontaneously in a C3H mouse in the
laboratory of Dr H.D. Suit (Massachusetts General Hospital,
Boston). The derivation of the cell line and details of its
handling have been published (Hirst et al., 1983). CHO V-3
cells (Whitmore et al., 1989) were obtained courtesy of G.F.
Whitmore, U. of Toronto. XR-1, a cell cycle specific gamma-
ray sensitive CHO cell mutant (Stamato et al., 1983) and its
parent, 4364, a proline and glycine auxotrophic mutant from
the CHO-Kl cell line, were obtained courtesy of T. Stamato,
Wistar Institute, Phil, PA. Cells were cultured in alpha MEM
or Waymouth's (SCCVII cells) supplemented with fetal
bovine serum (FBS); 10% for HT 1080, V-3, 4364 and XR-1,
15% for AG 1522 and SCCVII or 20% for AT5BI cells. A
final concentration of 0.025 mg ml ' penicillin and
0.04mgmlhl streptomycin were also added.
SR 4233 cytotoxicity assays
For hypoxic treatment, logarithmically growing cells in
60 mm glass petri dishes with notched sides (to facilitate gas
exchange) were treated with SR 4233 in 2 ml medium. The
dishes were placed into pre-warmed aluminium gassing
chambers and a vacuum was applied to reduce the air to
0.1 atmosphere. The chambers were then gassed with ultra
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pure N2 containing 5% CO2 at a flow rate of 1.0 litre min -.
The evacuation and N2 gassing were repeated five times with
a 1 min interval between the final two gassings. To expedite
gas exchange between the media and air, the aluminium
chambers were continuously shaken during the procedure.
After the final gassing the chambers were sealed and
incubated at 37°C on a shaker for 1.5 h. The temperature of
the media decreased by 3-4°C during the 5 min gassing
procedure, then rose back to 37°C within 15 min after thejigs
were placed in the incubator. For aerobic treatment, cells in
60 mm plastic dishes were exposed to SR 4233 for 1.5 h while
gassing with 5% CO2 in air at 37°C. The drug was then
removed and the dishes were rinsed, trypsinised, and the cells
counted, diluted and plated in 100mm plastic dishes. The
rinsing and plating was sufficient to dilute the residual drug
concentration by a factor of >8 x 104. After 8 days (for
rodent cell lines) or 12 days (for human cells), dishes were
fixed and stained with 1% crystal violet and colonies contain-
ing > 50 cells were counted. Plating efficiencies ranged from
20% (AT) to 75% (CHO).
SR 4233 metabolism studies
Metabolism of SR 4233 in cells was measured as previously
described (Baker et al., 1988). Exponentially growing cells
were trypsinised, pelleted, and resuspended at 1-5 x 107 cells
per ml in a bicarbonate buffered balanced salts solution
(BBS), pH 7.4 BBS contained per litre: 7.53 g NaCl, 2.2 g
NaHCO3, 0.4 g KCI, 0.46 g KH2PO4, 0.14 g CaC12, 0.1 g
MgCl2 6H2O, 0.1 g MgSO4-7H2O, 0.9 g glucose. Use of BBS
decreased quenching caused by medium and serum. Cells
were incubated at 37°C for 15 min to allow cellular respira-
tion of residual oxygen, then were then added to glass stirr-
ing vessels containing the desired concentration of drug that
had already been gassed for I h with humidified, ultra-pure
N2 containing 5% CO2. Samples were removed at 30 min
intervals, pelleted, and an equal amount of a 50% methanol,
2% acetic acid solution was added to the supernatant. The
amount of SR 4317 present in the supernatant was deter-
mined by fluorescence spectroscopy (emission = 416 nm,
excitation = 516 nm). At equimolar concentrations, SR 4317
is 64-fold more fluorescent at these wavelengths than
SR 4233 (unpublished data).
High performance liquidchromatography (HPLC)
Amounts of SR 4233, SR 4317 and SR 4330 were assayed by
isocratic reverse phase chromatography, using a Waters
HPLC system equipped with a WISP pump (Model 600A), a
steel 30 cm C,8 yBondapak column, and a variable absorb-
ance detector (Model 450) at 240 nm. Elution time and peak
area were integrated by a data module 730. The mobile phase
was 25% methanol/I% acetic acid at a flow rate of 1.3 ml
min '. SR 4233 eluted at 4.6 min; SR 4317 eluted at
12.81 min and SR 4330 eluted at 12.02 min. Loss of SR 4233
and formation of SR 4317 were calculated from the peak
areas by using area per concentration ratios derived from
standards for each of the species run on the same day as the
samples.
Complementation studies
XR-l cells were grown in 100#AM 6-thioguanine (6TG) to
select for mutants deficient in hypoxanthine guanine phos-
phoribosyltransferase (HPRT). Clonal isolates were then
grown in the presence of 1 mM ouabain and resistant
mutants were grown to confluence. Cell fusion was per-
formed by the technique of Davidson & Gerald (1976). XR-
1/6TGR/OUR cells (1 x 106/T-25 cm2 flask) were seeded with
V-3 cells and incubated overnight. Cells were washed twice
with media without serum and treated with a 45% poly-
ethylene glycol 1000, 7.5% dimethylsulfoxide solution in
alpha medium. The solution was diluted 1:10 and cells were
incubated for one additional minute before being washed
5 x with alpha MEM + 10% FCS. After 24 h incubation,
cells were reseeded and supplemented with HATO (1 x 10-4 M
hypoxanthine, 4 x 10-7M aminopterin, 1.6 x 10-5 M thy-
midine, 1 mM ouabain). Viable hybrids were then irradiated
with a "'Cs source at a dose rate of 700 rad/min and assayed
for clonogenic survival.
Results
Cytotoxicity ofhuman cells by SR 4233 in air andnitrogen
Under the gassing procedure used, we determined that com-
plete 'radiobiological' hypoxia was achieved rapidly
(< 5 min) and remained at steady state levels of < 100 p.p.m.
02 during the 90min treatment time (Brown & Kuruppu,
unpublished). Figure 2 shows the cytotoxicity ofdifferent cell
lines to SR 4233 under hypoxia. Murine SCCVII cells were
the most sensitive to SR 4233 under hypoxia with an LD50 of
3,LM. Repair deficient XR-1, V-3 and ATSBI cells were also
sensitive (LDm = 5tLM) while SR 4233 was less cytotoxic to
AG 1522 (LD50 = 18pM), CHO 4364 (LD50 = 25tLM) and
HT 1080 cells (LD50 = 33 pM).
In all cell lines SR 4233 was more cytotoxic under nitrogen
than under air (Figure 3a and b). The ratios of aerobic to
hypoxic cytotoxicity (HCR) were between 100-200, regard-
less of the origins ofthe cell lines (except for 4364, which was
20-50).
Reduction ofSR 4233 to SR 4317 under hypoxia
To help explain the differential sensitivity, the rate of reduc-
tion of SR 4233 to SR 4317 in human and murine fibroblasts
was determined. SR4233 is reduced under hypoxia to the
1-oxide reduction product, SR4317, which is much more
fluorescent than SR4233, thus facilitating its detection by
fluorescence spectroscopy. Production of SR 4317 was shown
to be linear over a 3 h treatment period in all cell lines tested
(Figure 4). Formation of SR 4317 and SR 4330 was verified
by HPLC (Figure 5). All cells lines remained metabolically
active during the 3 h time course (data not shown). ATSBI
and SCCVII cells showed the highest rates of metabolism of
SR 4233 with 21.8 and 18.9 fmol h-' cell-', while AG 1522,
XR-1, HT 1080, 4364 and V-3 showed lower reduction rates
of 10.4, 8.7, 6.7, 5.5 and 5.3 fmolh' cell-', respectively.
Gamma-ray analysis ofhybrids
XR-1 cells made resistant to ouabain and 6TG displayed
similar Do values to irradiation as the sensitive XR-1 popula-
tion (Figure 6). XR-1 OURTGR x XR-l or V-3 x V-3 hybrids
were as sensitive to irradiation as the XR-1 or V-3 popula-
tion alone. XR-1 OURTGR x V-3 hybrids were more resistant
to X-ray and had a dose response curve similar to that ofthe
repair proficient 4364 parental cells, thereby demonstrating
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Figure 2 A comparison of the cytoxocity of rodent and human
lines by SR 4233 under hypoxia. Repair-competent (open sym-
bols) SCCVII (0), AG 1522 (0), 4364 (A), HT 1080 (0) and
repair-deficient (shaded symbols) AT5BI (A), XR-1 (O) V-3 (0)
were exposed under hypoxia to a 90 min treatment of SR 4233.
Each point represents the geometric mean of >3 experiments.360 K.A. BIEDERMANN et al.
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Figure 3 Cytotoxicity of a, human and b, rodent lines by
SR4233 under aerobic (shaded symbols) or hypoxic conditions
(open symbols). .
AVG METABOLIC RATE
fmol SR 4317 h-1 cell-'
A AT5BI 21.8 ± 5.3
o SCC VII 18.9 ± 1.0
A AG 1522 10.4 ± 1.5
* XR-1 8.7 ± 1.4
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6.7 ± 0.7
5.5 ± 2.1
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Figure 4 Reduction of SR 4233 to SR 4317 under hypoxia in
human and murine fibroblasts. Substrate concentration = 200gM
SR 4233.
that XR-1 and V-3 cells belong in different complementation
groups.
Relationship between SR 4233 sensitivity andmetabolism
LD98 values were obtained from extrapolation values in
Figures 2 and 3 and were plotted against the rate of
metabolism for each cell line. For all repair competent cells
as well as AT5BI, the sensitivities to SR 4233 under hypoxia
correlated well with the rates of SR 4233 metabolism (Figure
7a). No correlation was observed when we compared aerobic
sensitivities (as measured by LD90 concentrations) to that of
hypoxic SR 4233 metabolism (Figure 7b). The cell lines
SCCVII and AT5BI displaying the highest sensitivity to
SR 4233 under hypoxia also metabolised the drug to the
greatest extent. However, the rodent V-3 and XR-1 cells,
which are deficient in repair of double strand breaks, were
more sensitive to killing by SR 4233 under hypoxia than
could be accounted for by their rates of drug metabolism.
Discussion
The results shown here demonstrate that rodent and human
cells are preferentially susceptible to killing by SR 4233 under
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Figure 5 Reduction of SR4233 and formation of SR4317 and
SR4330 as measured by HPLC in SCCVII a, and HT 1080 b,
cells.
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Figure 6 Gamma-ray sensitivity of XR-1 x V-3 hybrids. Symbols:
4364 (0), XR-1/TGR/OUR x V-3 (0), XR-1/TGR/OUR x XR-4
(U), XR-1 (0), V-3 (A).
hypoxia. However, the absolute sensitivity of the cells under
both aerobic and hypoxic conditions varied over a wide
range (LD_o = 50-200 giM under aerobic conditions and from
3-33 gM under hypoxia). The differential toxicity (ratio of
drug concentration under aerobic to hypoxic conditions to
produce the same degree of cell killing) was 100-200 for all
cell lines except the CHO 4364 line (ratio = 20). We show
from these data that the variation in hypoxic sensitivity of
the repair competent cell lines could be entirely accounted for
by their different rates of drug metabolism. We have also
found that in SCCVII (most sensitive) and HT 1080 (least
sensitive) cell sonicates, Km values were similar, whereas V,,
values were 3-fold higher in SCCVII sonicates (unpublished
data). This indicates that similar enzyme(s) are responsible
for toxicity and that the hypoxic sensitivity of cell lines to
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Figure 7 Relationship between SR 4233 cytotoxicity under
hypoxic a, or under aerobic conditions b, and metabolism rate of
SR 4233 under hypoxia.
SR 4233 is a result of differing concentrations of these
enzymes.
Interestingly, hypoxic metabolism did not predict the
aerobic sensitivities of cells to SR 4233. It is possible that the
production of superoxide radicals during the metabolism of
SR 4233 in air may be responsible for the aerobic toxicity.
Thus, the toxicity of SR 4233 in air may be dependent not
only on the amount of reductive enzyme, but also on the
concentrations of oxygen radical scavengers or perhaps
catalase or GSH-associated enzymes present in these cells.
This correlation of drug sensitivity under hypoxia with the
rate of drug metabolism did not hold for the two CHO
mutants, XR-1 and V-3, which are sensitive to ionising radia-
tion due to a deficiency in DNA double strand break rejoin-
ing (Stamato et al., 1983; Whitmore et al., 1989). Comp-
lementation studies showed that both these cell lines repre-
sent separate DNA repair deficient mutants. XR-1 and V-3
were found to be more sensitive to SR 4233 under hypoxia
than predicted by their metabolism rate.
We conclude that the toxicity by SR 4233 in cells appears
to result from two mechanisms; first, the rate of drug
metabolism in individual cell lines, and second, the ability of
cells to repair DNA double strand breaks produced by the
drug. This suggests that the primary mechanism of hypoxic
cell killing by SR 4233 is by the production of DNA double
strand breaks. It should be noted, however, that the human
fibroblastic cell line AT5BI, despite being X-ray sensitive,
was not more sensitive to SR 4233 killing under hypoxia than
predicted from its rate of metabolism of SR 4233. This may
be related to the fact that AT cells have not shown a gross
defect in DNA double strand break rejoining, although they
do show reduced rejoining of chromosome breaks compared
to normal cells (Cornforth & Bedford, 1985), and lack the
ability to repair poterftially lethal damage as judged by
delayed plating experiments (Biedermann & Brown, 1989).
This lack of correlation between X-ray and SR4233 sen-
sitivity is also seen in the data of Keohane et al. (1990).
These investigators showed that irs cells, which are radiation-
sensitive, but not deficient in the repair of DNA double
strand breaks (Jones et al., 1990), display similar hypoxic
cytotoxicities by SR 4233 to the parental V79 vells. It would
therefore appear that radiation sensitivity per se in the
absence of a defect in double strand break rejoining is not a
sufficient condition for sensitivity to SR 4233. This points to
a possible difference in the mechanism of cell killing by
radiation and SR 4233.
An important application of the present data is that it
should allow a rapid means of predicting the sensitivity of
individual human tumours to SR 4233 should this drug
become used in the clinic. It would be relatively easy to
characterise the likely drug sensitivity of such tumours by a
measurement of the rate of metabolism of SR 4233 under
hypoxia in a suspension or homogenate of the tumour cells.
High rates of drug metabolism would indicate high drug
sensitivity and the greater likelihood of tumour cell kill.
The authors would like to thank Drs T. Stamato for providing us
XR-1 cells and G.F. Whitmore for providing us V-3 cells. We also
thank Dr Amato Giaccia for assistance with the complementation
studies and critical review of the manuscript and Jim Evans for the
HPLC analysis. This work was supported by grant number
CA 15201, from the national Cancer Institute, DHHS, and by PHS
Grant Number CA 09302, awarded to K.A.B. by the National
Cancer Institute, DHHS.
References
BAKER, M.A., ZEMAN, E.M., HIRST, V.K. & BROWN, J.M. (1988).
Metabolism of SR 4233 by Chinese Hamster Ovary Cells: Basis
of Selective Hypoxic Cytotoxicity. Cancer Res., 48, 5947.
BIEDERMANN, K.A. & BROWN, J.M. (1989). Comparison between
X-rays and SR4233 for cytotoxicity and repair of potentially
lethal damage in human cells. Int. J. Radiat. Biol., 56, 813.
BROWN, J.M. (1987). Exploitation of bioreductive agents with
vasoactive drugs. Rad Res: Proceedings of the 8th International
Congress of Radiation Research, 2, 719.
BROWN, J.M. & LEMMON, M.J. (1990). SR4233: a tumor specific
radiosensitizer active in fractionated radiation regimes. Radiother.
and Oncol. (in press).
CORNFORTH, M.N. & BEDFORD, J.S. (1985). On the nature of a
defect in cells from individuals with ataxia-telangiectasia. Science,
227, 1589.
DAVIDSON, R.L. & GERALD, P.S. (1976). Improved techniques for
the induction of mammalian cell hybridization by polyethylene
glycol. Somat. Cell Genet., 2, 165.
HIRST, D.G., BROWN, J.M. & HAZLEHURST, J.L. (1983). Enhance-
ment of CCNU cytotoxicity by misonidazole: possible therapeutic
gain. Br. J. Cancer, 46, 109.
JONES, N.N., STEWARD, S.A. & THOMPSON, L.H. (1990). Bio-
chemical and genetic analysis of the Chinese hamster mutants irsl
and irs2 and their comparison to cultured AT cells. Mutagenesis,
5, 15.
KEOHANE, A., GODDEN, J., STRATFORD, I.J. & ADAMS, G.E. (1990).
The effects of three bioreductive drugs (mitomycin C, RSU-1069,
and SR 4233) on cell lines selected for their sensitivity to
mitomycin C or ionising radiation. Br. J. Cancer, 61, 722.
LADEROUTE, K.R. & RAUTH, A.M. (1986). Identification of two
major reduction products of the hypoxic cell toxin 3-amino-1,2,4-
benzotriazine-1,4-dioxide. Biochem. Pharmacol., 35, 3417.
LADEROUTE, K., WARDMAN, P. & RAUTH, M. (1988). Molecular
mechanisms for the hypoxia-dependent activation of 3-amino-
1,2,4-benzotrianzine-1,4-dioxide (SR 4233). Biochem. Phamacol.,
37, 1487.
STAMATO, T.D., WEINSTEIN, R., GIACCIA, A. & MACKENZIE, L.
(1983). Isolation of a cell cycle-dependent gamma ray-sensitive
Chinese hamster ovary cell. Somat Cell Genet., 9, 165.
SUN, J.R. & BROWN, J.M. (1989). Enhancement of the antitumor
effect of flavone acetic acid by the bioreductive cytotoxic drug
SR 4233 in a murine carcinoma. Cancer Res., 49, 5664.362 K.A. BIEDERMANN et al.
TANNOCK, I.F. & GUTTMAN, P. (1981). Response ofchinese hamster
ovary cells to anticancer drugs under aerobic and hypoxic condi-
tions. Br. J. Cancer, 43, 245.
THOMLINSON, R.H. & GRAY, L.H. (1955). The histological structure
of some human lung cancers and the possible implications for
radiotherapy. Br. J. Cancer, 9, 539.
WALTON, M.I., WOLF, C.R. & WORKMAN, P. (1989). Molecular
enzymology of the reductive bioactivation of hypoxic cell
cytotoxins. Int. J. Radiat. Oncol. Biol. Phys., 16, 983.
WHITMORE, G.F., VARGHESE, A.J. & GULYAS, S. (1989). Cell cycle
responses of two X-ray sensitive mutants defective in DNA
repair. Int. J. Radiat. Biol., 56, 657.
ZEMAN, E.M., BROWN, J.M., LEMMON, M.J., HIRST, V.K. & LEE,
W.w. (1986). SR4233: a new bioreductive agent with high selec-
tive toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol.
Biol. Phys., 12, 1239.
ZEMAN, E.M., HIRST, V.K., LEMMON, M.J. & BROWN, J.M. (1988).
Enhancement of radiation-induced tumor cell killing by the
hypoxic cell toxin SR4233. Radiother. Oncol., 12, 209.